Literature DB >> 22745334

Commentary: theoretical predictions of flow effects on intestinal and systemic availability in physiologically based pharmacokinetic intestine models: the traditional model, segregated flow model, and QGut model.

K Sandy Pang, Edwin C Y Chow.   

Abstract

Physiologically based pharmacokinetic (PBPK) models for the intestine, comprising of different flow rates perfusing the enterocyte region, were revisited for appraisal of flow affects on the intestinal availability (F(I)) and, in turn, the systemic availability (F(sys)) and intestinal versus liver contribution to the first-pass effect during oral drug absorption. The traditional model (TM), segregated flow model (SFM), and effective flow (Q(Gut)) model stipulate that 1.0, ∼0.05 to 0.3, and ≤0.484× of the total intestinal flow, respectively, reach the enterocyte region that houses metabolically active and transporter-enriched enterocytes. The fractional flow rate to the enterocyte region (f(Q)), when examined under varying experimental conditions, was found to range from 0.024 to 0.2 for the SFM and 0.065 to 0.43 for the Q(Gut) model. Appraisal of these flow intestinal models, when used in combination with whole-body PBPK models, showed the ranking as SFM < Q(Gut) model < TM in the description of F(I), and the same ranking existed for the contribution of the intestine to first-pass removal. However, the ranking for the predicted contribution of hepatic metabolism, when present, to first-pass removal was the opposite: SFM > Q(Gut) model > TM. The findings suggest that the f(Q) value strongly influences the rate of intestinal metabolism (F(I) and F(sys)) and indirectly affects the rate of liver metabolism due to substrate sparing effect. Thus, the f(Q) value in the intestinal flow models pose serious implications on the interpretation of data on the first-pass effect and oral absorption of drugs.

Mesh:

Substances:

Year:  2012        PMID: 22745334     DOI: 10.1124/dmd.112.045872

Source DB:  PubMed          Journal:  Drug Metab Dispos        ISSN: 0090-9556            Impact factor:   3.922


  5 in total

1.  Physiologically-Based Pharmacokinetic Modeling of Macitentan: Prediction of Drug-Drug Interactions.

Authors:  Ruben de Kanter; Patricia N Sidharta; Stéphane Delahaye; Carmela Gnerre; Jerome Segrestaa; Stephan Buchmann; Christopher Kohl; Alexander Treiber
Journal:  Clin Pharmacokinet       Date:  2016-03       Impact factor: 6.447

Review 2.  ITC recommendations for transporter kinetic parameter estimation and translational modeling of transport-mediated PK and DDIs in humans.

Authors:  M J Zamek-Gliszczynski; C A Lee; A Poirier; J Bentz; X Chu; H Ellens; T Ishikawa; M Jamei; J C Kalvass; S Nagar; K S Pang; K Korzekwa; P W Swaan; M E Taub; P Zhao; A Galetin
Journal:  Clin Pharmacol Ther       Date:  2013-02-25       Impact factor: 6.875

Review 3.  Predicting Drug Extraction in the Human Gut Wall: Assessing Contributions from Drug Metabolizing Enzymes and Transporter Proteins using Preclinical Models.

Authors:  Sheila Annie Peters; Christopher R Jones; Anna-Lena Ungell; Oliver J D Hatley
Journal:  Clin Pharmacokinet       Date:  2016-06       Impact factor: 6.447

4.  A comparative evaluation of models to predict human intestinal metabolism from nonclinical data.

Authors:  Estelle Yau; Carl Petersson; Hugues Dolgos; Sheila Annie Peters
Journal:  Biopharm Drug Dispos       Date:  2017-04       Impact factor: 1.627

Review 5.  The Segregated Intestinal Flow Model (SFM) for Drug Absorption and Drug Metabolism: Implications on Intestinal and Liver Metabolism and Drug-Drug Interactions.

Authors:  K Sandy Pang; H Benson Peng; Keumhan Noh
Journal:  Pharmaceutics       Date:  2020-04-01       Impact factor: 6.321

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.